NavigateandExploreourWebsite'sStructureandContent

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySite Kit 

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

PagesCertifications & AccreditationsWebinar: Advancing personalized cancer treatment: explore the synergy of Twist Bioscience & OncoDNAHomepage_DevelTwist WebinarAwardsFor Clinical ResearchSNP GenotypingEpigenomicsTranscriptomicsDNA/RNA SequencingFor Oncology ProfessionalsOncoFOLLOW : Personalized liquid biopsy for patient monitoringOncoDEEP® : Our comprehensive cancer biomarker testOncoSELECT® : Our biomarker test on liquid biopsyFor Biotechs and Pharma professionalsKnowledge-driven medicinePrecision enrollmentClinical TestingMolecular Residual Disease (MRD) for PharmaTeamFor Laboratory ProfessionalsLiquid Biopsy (OncoSELECT Kit)Molecular Residual Disease (MRD)Clinical Data Intelligence (OncoCDI)Solid Biopsy (OncoDEEP®)CareersDownload OncoDEEP reportRequest a DemoOrder KitAbout Biological (Mercury™)Clinical and biological interpretation (OncoKDM)Our Blog & Home
Posts
ArticleOncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing services - 23 February 2024
Case of the MonthMarch: 42-year-old male with a metastatic colorectal cancer - 18 March 2024February: 40-year-old male with a stage IV glioma cancer - 20 February 2024January: 45-year-old male with an intrahepatic cholangiocarcinoma - 16 January 2024December: 52-year-old male with a stage IV gastric cancer - 19 December 2023November: 68 year-old man with a Stage IV Prostate cancer - 14 November 2023October: 65 year-old woman with a Metastatic Breast Cancer with hormone receptor (HR)-positive - 31 October 2023September: 53 year-old man with Metastatic Colorectal Cancer - 29 September 2023July: 53 year-old man with Non-Small Cell Lung Cancer - 24 July 2023HRD in Ovarian Cancer Treatment: 60 year-old woman with Metastatic Ovarian Cancer - 16 May 2023
Lab CaseEnhancing HRD Genomic Scar Result Interpretation: New Insights and Strategies - 29 September 2023Revolutionizing laboratory operations with OncoDEEP® Kit - 18 June 2023
PosterGenome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer - 22 January 2024Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers - 8 January 2024Ultra-sensitive detection of MRD through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer - 12 December 2023ctDNA’s promise in early detection of MRD and recurrence prediction for Head and Neck Squamous Cell Carcinoma - 2 November 2023Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD) - 19 October 2023
Press ReleaseLeading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument. - 28 February 2024Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccine - 17 January 2024OncoDNA laboratory has received the CAP accreditation - 4 January 2024OncoDEEP Kits enable routine NGS workflow at the Institute of Pathology, Klinikum Region, Hanover, Germany - 4 December 2023OncoDNA supports the extension of AURORA study to identify molecular changes driving metastatic breast cancer - 23 November 2023OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands - 7 November 2023OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house - 20 October 2023C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe - 19 October 2023OncoDNA announces the closing of a round C financing of 6,5 M€ - 3 July 2023Collaboration between OncoDNA and Eli Lilly Italia to broaden access to biomarker testing for thyroid cancer patients - 24 November 2022Berkshire and Surrey Pathology Services & OncoDNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK - 18 October 2022OncoDNA announces the operational launch of its OncoDEEP® Kit for comprehensive genomic profiling of solid tumors - 12 September 2022OncoDNA and Synlab partner to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany - 29 March 2022OncoDNA launches OncoDEEP® Kit for comprehensive biomarker testing of solid tumors - 10 February 2022C2i Genomics partners with OncoDNA to bring AI-powered liquid biopsy for cancer diagnostics across Europe - 10 January 2022OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology - 16 December 2021OncoDNA provides strategic support in Radiomics’ prospective clinical trial SALMON - 25 November 2021OncoDNA teams up with SOPHiA GENETICS to enable laboratories to establish data-driven medicine as a standard of care - 30 September 2021New partnership to advance identification of best treatments for cancer patients - 9 August 2021Collaboration between Bayer Saudi Arabia LLC, OncoDNA and Tamkin Al-Seha Medical to test cancer patients for rare NTRK mutations in Saudi Arabia - 13 July 2021Institut Jules Bordet collaborates with OncoDNA to explore biology of brain metastases using personalized liquid biopsy from cerebrospinal fluid - 17 June 2021OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers - 15 April 2021Fighting cancer with personalized vaccines: OncoDNA and myNEO join forces to unlock the power of mRNA therapeutics - 7 April 2021OncoDNA supports BSMO project to advance precision medicine for late stage cancer patients across Belgium - 4 February 2021OncoDNA appoints Dr Bernard Courtieu as Chief Executive Officer - 25 January 2021OncoDNA announces expansion of its services into the United States - 7 January 2021OncoDNA wins the Biotech Award of Deloitte’s 2020 Technology Fast50 competition - 27 November 2020New molecular diagnostic innovation partnership to facilitate patient access to personalised cancer care across the UK - 24 November 2020Successful friendly takeover bid initiated by OncoDNA on IntegraGen’shares - 17 November 2020OncoDNA has been nominated for the Deloitte’s 2020 Technology Fast 50 - 10 November 2020American Hospital of Paris and OncoDNA Partner to Advance Breast Cancer Patients Management - 13 October 2020OncoDNA signs collaboration agreement with the European Cancer Patient Coalition on the 2020 personalised medicine awareness project - 24 September 2020OncoKDM® used as the support SaaS platform in a prospective pilot study of Veneto Institute of Oncology – IRCCS - 10 September 2020OncoDNA has been nominated for the 2020 BVA Award Growth of the Year - 8 September 2020ONCODNA provides an update about the friendly takeover bid on INTEGRAGEN - 12 August 2020Agreement to file a friendly takeover bid initiated by OncoDNA on IntegraGen to acquire all outstanding shares at a price of 2.20€ per share - 9 July 2020
Scientific Application NoteCancer Management: Breast Cancer - 24 July 2023Comprehensive Ovarian Cancer Treatment and Management - 9 June 2023Advanced lung cancer treatment and diagnostic solutions - 15 May 2023ctDNA as predictive biomarker of everolimus efficacy in advanced luminal breast cancer - 4 October 2021OncoDNA supports the AURORA study to identify molecular changes driving metastatic breast cancer - 6 July 2021Analysis of prognostic and predictive factors of response in squamous cell carcinoma using comprehensive biomarker testing - 21 May 2021BRCA1/2 mutation detection in breast cancer tumor tissue using NGS and OncoKDM - 12 May 2021Study assesses the clinical activity of tipifarnib for HNSCC patients with HRAS mutations using OncoKDM - 21 April 2021The economics of comprehensive biomarker testing in cancer - 24 March 2021When is the optimal time for biomarker testing in the patient pathway? - 26 February 2021ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report - 23 February 2021Something old, something new: when is a new biopsy preferable for biomarker analysis? - 31 January 2021Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) - 21 January 2021The evolution of BRCA testing: treatment & prevention opportunities - 20 December 2020Biomarker testing and horizon scanning help plan future treatments for patients - 19 November 2020What’s on the horizon for immunotherapy? - 15 October 2020The current landscape of biomarker directed therapy in oncology - 16 September 2020COVID-19 Pandemic : Determinants of COVID-19 disease severity in patients with cancer - 20 August 2020COVID-19 Pandemic : Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis - 20 August 2020Lung Cancer : Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis - 20 August 2020Brain Tumours : MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas - 20 August 2020Immunotherapy : Escape from nonsense-mediated decay associates with anti-tumor immunogenicity - 20 August 2020The fluid landscape of liquid biopsy - 13 August 2020Endometrial Cancer Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002) - 11 August 2020Biliary Tract Cancer Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial - 11 August 2020BREAST CANCER Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer - 11 August 2020Oncology in the time of COVID - 15 July 2020COVID-19 PANDEMIC: Modelling from the US National Cancer Institute (NCI) predicts the pandemic will result in an excess of over 10,000 deaths from breast and colorectal cancer in the USA, due to missed screening and delayed therapy. - 29 June 2020DRUG TARGETS: A novel ATR inhibitor has cleared phase I development with manageable toxicity; responses were seen in tumours harbouring ATM/ARID1A and BRCA1 alteration (colorectal and ovarian respectively) - 29 June 2020BLADDER CANCER: In a retrospective analysis, both ARID1A mutation and CXCL13 expression showed positive correlation with response to checkpoint inhibition, including overall survival. Combining the markers improved prediction. - 29 June 2020GASTROINTESTINAL CANCER: Promising results from a small phase Ib study of regorafenib + nivolumab in advanced gastric or colorectal cancer: ORR 44% & 36% respectively. - 29 June 2020CANCER PREVENTION The American Cancer Society (ACS) have updated their diet and physical exercise guidelines to advise avoidance of all alcohol, a change from previous guidance advising moderation. - 22 June 2020BREAST CANCER For newly diagnosed ER+ disease, neoadjuvant anti-oestrogen therapy may be an acceptable bridge to surgery in the face of COVID-19 related delays - 22 June 2020RENAL CANCER In a retrospective analysis, rechallenge with immunotherapy delivered ORR 23% (compared with 37% ORR for first exposure); responses at rechallenge were not restricted to those who had responded at first exposure. - 22 June 2020LYMPHOMA The FDA have approved the EZH2 inhibitor tazemetostat in folliciular lymphoma, third line for EZH2-mutant disease, or where there are no other treatment options for EZH2 wild-type disease - 22 June 2020LUNG CANCER Using genomic analysis to ascertain loss of heterozygosity at the HLA locus in combination with tumour mutational burden (TMB) provided better prediction of response to immunotherapy compared with TMB alone. - 22 June 2020IMMUNOTHERAPY The FDA have granted pan-cancer approval for the PD-1 inhibitor pembrolizumab for cancers with tumour mutational burden >10 mut/mb, adult and paediatric. - 22 June 2020COVID-19 PANDEMIC Urgent referrals for suspected cancer were down 60% in April in the UK; some cancer types were differentially affected with suspected breast cancer referrals down 78%. - 22 June 2020CHOLANGIOCARCINOMA A small single arm study of PD-1 inhibition (nivolumab) for previously treated biliary tract cancers showed ORR 11% - 26 May 2020DRUG TARGETS: MET A phase I study of an anti-MET antibody (telisotuzumab) in advanced cancers reported partial responses in MET amplified tumours - 26 May 2020DRUG TARGETS: KRAS Disappointing results from ASCO of the KRAS G12C inhibitor (AMG-510), with a study in colorectal cancer and a basket study of non-NSCLC/CRC indications both delivering ORR 12%. - 26 May 2020PROSTATE CANCER: A PROTAC-based androgen receptor degrader has shown anti-tumour activity in first in human studies presented at ASCO. - 26 May 2020PROSTATE CANCER The FDA have granted accelerated approval to the PARP inhibitor rucaparib for BRCA-mutated (germline or somatic) metastatic castrate-resistant disease. - 26 May 2020MELANOMA: In a retrospective study of patients with advanced disease who achieved a complete response to immunotherapy, cessation of therapy was associated with a 27% risk of subsequent disease progression. - 26 May 2020HEPATOCELLULAR CANCER Combination PD-L1 and VEGFR inhibition (atezolizumab plus bevacizumab) delivered better overall and progression-free survival than standard of care sorafenib in a pivotal phase 3 study. - 26 May 2020LUNG CANCER: The FDA have approved the MET inhibitor capmatinib for advanced NSCLC harbouring MET exon 14 skipping. Approval is based on ORR of 68% and 41% for treatment-naive and previously treated patients, respectively - 11 May 2020LUNG CANCER: Data from TRACERx presented at AACR provides further support for the use of personalised ctDNA assays in the assessment of minimal residual disease and impending progression following surgery for early stage disease - 11 May 2020GASTRIC/COLORECTAL CANCER: Promising early efficacy data for combined regorafenib plus nivolumab: ORR 44% and 36% for gastric and colorectal respectively, all bar one with microsatellite stable disease - 11 May 2020MELANOMA: The addition of PD-L1 blockade (atezolizumab) to combined BRAF/MEK inhibition (vemurafenib + cobimetinib) improved PFS as first line therapy in advanced BRAF V600 mutant melanoma. Survival data are awaited - 11 May 2020PANCREATIC CANCER: Addition of a PARP inhibitor (veliparib) to gemcitabine + cisplatin chemo did not improve outcomes for patients harbouring germline mutations in BRCA1/2 or PALB2 - 11 May 2020EARLY CANCER DETECTION: Data from GRAIL presented at AACR indicate continued progress in the development of a methylation-based ctDNA assay with high specificity for the early detection of cancer - 11 May 202047% of cancer overall positive response to treatment thanks to OncoDEEP combined tumour molecular profiling - 11 May 2020
Scientific ReviewScientific Review: Latest Discoveries in Oncology - 3 October 2023
TestimonialRevolutionizing precision medicine: OncoDNA’s data innovation story - 3 July 2023Comprehensive genomic profiling in oncology: A revolutionary approach by Marcel Trautmann - 11 May 2023
VideoDecoding Cancer: OncoDEEP Kit revolutionises genomic analysis for personalised treatment - 15 November 2023Testimonial of OncoDNA’s Journey through its founder’s words - 22 August 2023Precision oncology solutions: From molecular profiling to clinical decision with OncoKDM - 13 May 2023
WebinarAdvancing personalized cancer treatment: Webinar Replay - 19 February 2024Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinar - 22 January 2024
White paperEnsuring a Robust DNA Analysis and the Best Clinical Interpretation by Generating a High-Quality Data Set - 6 June 2023White Paper: Homologous Recombination Deficiency (HRD) Assessment for Clinical Management using the OncoDEEP® Kit - 14 May 2023

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

Company 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Project Care
Resources
OncoDNA Group
Patients & Relatives
Cookie Policy (EU)

Contact

Submit complaint

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129318